Inhibitors of immune checkpoint proteins, such as Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and Programmed cell death protein 1 (PD1), are now established standards of care across a diverse range of solid and haematological cancers that include melanoma, lung cancer, and lymphomas. Here, CTLA4 is linked to lymphoma.